热门关键词:亚博网页版,亚博登录,亚博入口  
当前位置:首页 > 企业新闻
基因测试或将助乳腺癌患者避免化疗:亚博网页版
2021-02-23 [90836]
本文摘要:More than a hundred thousand women diagnosed with breast cancer in Europe and the US each year could avoid chemotherapy by taking a gene test made by Agendia, a Dutch biotech group, which can attempt to predict whether the disease is likely to return.通过拒绝接受一家荷兰生物科技集团Agendia研发的一项基因测试,每年发病患上乳腺癌的逾10万名欧美女性有可能不用拒绝接受化疗。

More than a hundred thousand women diagnosed with breast cancer in Europe and the US each year could avoid chemotherapy by taking a gene test made by Agendia, a Dutch biotech group, which can attempt to predict whether the disease is likely to return.通过拒绝接受一家荷兰生物科技集团Agendia研发的一项基因测试,每年发病患上乳腺癌的逾10万名欧美女性有可能不用拒绝接受化疗。Agendia可以尝试预测癌症若无发作有可能。

亚博入口

亚博登录

亚博入口

亚博登录

亚博入口

Women with early-stage breast cancer are often given chemotherapy after surgery if their tumours are over a certain size or have started to spread to the lymph nodes, factors which suggest they have a high clinical risk of suffering a recurrence.被发病患上早期乳腺癌的女性,如果肿瘤尺寸多达一定范围或者开始蔓延到淋巴结(这些因素似乎,癌症发作的临床风险十分低),那么一般来说不会在手术之后拒绝接受化疗。But many of them are believed to gain little benefit from undergoing the punishing therapy.但据信她们中许多人拒绝接受这种虐待人的化疗之后,完全没接到任何疗效。

亚博入口

According to the results of a large clinical study, to be published in the New England Journal of Medicine (NEJM) on Thursday, 根据周四公开发表于《新英格兰医学杂志》(NEJM)上的一项大型临床研究的结果,patients who were deemed by the test to have a low genomic risk of recurrent cancer — and who subsequently did not receive chemotherapy — had a similar chance of surviving compared with those who were given the toxic treatment.测试后被指出从基因组角度取决于癌症发作风险很低——并且随后没拒绝接受化疗——的患者,其存活概率跟那些拒绝接受了这种有毒性的疗法的患者差不多。Agendia said that of the roughly 445,000 women diagnosed with early-stage breast cancer each year in Europe and the US, around 102,000 of them could be able to forego chemotherapy after taking the so-called MammaPrint test.Agendia回应,在约44.5万名每年被证实患上早期乳腺癌的欧美女性中,10.2万人在经过所谓MammaPrint测试之后,有可能有能力退出化疗。The MammaPrint test costs roughly $3,000, but could result in a net reduction in healthcare costs given that a round of chemotherapy costs about $26,000 per patient.MammaPrint测试的费用大约为3000美元,但鉴于每名患者的一轮化疗费用大约为2.6万美元,该测试有可能构建医疗费用的净增加。The five-year clinical study of more than 5,000 women found that 94.7 per cent of patients who were categorised as lower-risk by the test survived without their cancer returning and spreading to other parts of the body, about 1.5 per cent lower than those who did receive chemotherapy.针对逾5000名女性、为期5年的临床研究找到,在被MammaPrint测试指出发作风险更加较低的患者中,94.7%的人活着了下来,癌症未发作或者蔓延到身体其他部位,比起显然拒绝接受过化疗的患者较低了1.5%。

亚博入口

亚博登录

亚博入口

The MammaPrint test scans biopsies of tumours for 70 genes that govern whether cancerous cells are likely to multiply or invade healthy tissues to determine if there is a high chance of the disease returning even after patients have undergone surgery.MammaPrint测试对肿瘤的活体的组织切片展开扫瞄,查询掌理癌细胞否可能会交配或侵略身体健康的组织的70种基因,从而判断在患者即便经历手术之后,癌症发作的可能性否很高。The findings come as oncologists try to find treatment plans that are less burdensome, especially for women suffering from breast cancer, who sometimes undergo major surgery such as a double mastectomy even when there is a low risk of their disease recurring.这一研究结果发布之时,肿瘤学家们于是以尝试找寻开销更加小(特别是在是对乳腺癌女患者而言)的化疗方案。即使癌症发作的风险很低,这些女患者有时也不会展开双侧乳腺手术等大手术。

亚博入口


本文关键词:亚博网页版,亚博登录,亚博入口

本文来源:亚博网页版-www.afarmaciagranados.com